Cosm Medical achieves FDA clearance for Gynethotics™ Pessaries, pioneering the future of personalized pelvic care

Ontario Industry UpdatesOBIO News
Written By Arsheen Kaur

Cosm Medical achieved FDA clearance for Gynethotics™ Pessaries, marking it as the first personalized pessary available to patients. This milestone follows a recent Health Canada clearance and marks a significant advancement in pelvic care, emphasizing Cosm’s commitment to enhancing patient outcomes and revolutionizing treatment options for women worldwide.

Cosm Medical is an OBIO® member, an alumnus of our BDSP™, CAAP®, H2BB™, HealthMINT™ and WiHI programs, and presented at the OBIO® Investment Summit.

Arsheen Kaur
Previous

Domain Therapeutics and Chime Biologics join forces to advance novel anti-CCR8 antibody for cancer immunotherapy
Next

OBIO® Celebrates International Women’s Day with Investment in Three Women-Led Companies and a Successful Graduation of First Seed Funding Cohort